ABBV:NYSEAbbVie Inc. Analysis

AbbVie’s stock is trading at $252.74, comfortably above its 20‑day ($238.05), 50‑day ($221.86) and 200‑day ($222.53) moving averages, and the MACD shows a bullish crossover with a positive histogram of 1.26. However, the RSI of 66 signals the shares are approaching overbought territory and the price sits just below the 52‑week resistance of $261.64, limiting near‑term upside. The DCF‑derived fair value of $222.43 suggests the market is pricing in a modest 2.2% upside, while the trailing P/E of 125x dwarfs the industry average of 29x, indicating the stock is currently overvalued despite a forward P/E of 15.5x that hints at improving earnings. AbbVie’s revenue grew 12.4% year‑over‑year to $62.8 B and margins remain robust (gross 72%, operating 32%), yet net profit margins are thin (5.8%) and the balance sheet is heavily leveraged with $72.9 B of debt against $9.4 B of cash, resulting in a negative book value per share.
Recent material news includes the acquisition of Apogee Therapeutics, FDA approval of a new therapy for a rare blood cancer, and strong Phase 3 data for a venetoclix‑based regimen, all of which reinforce the company’s growth narrative. The dividend yield of 2.72% looks attractive, but a payout ratio exceeding 300% raises concerns about sustainability. Combined with a high debt load, negative equity, and a modest upside forecast, the stock presents a mixed picture of growth potential tempered by valuation and financial risks.